Vectus Biosystems Ltd (ASX:VBS) has listed on the ASX after raising A$5.1 million through an IPO to continue its search for an effective treatment for fibrosis and high blood pressure.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced completion of a review of safety from the first cohort of 10 patients in the STEP trial.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine technology company, today announced that the Australian Patent Office has granted a patent covering the use of cancer vaccine technology for the treatment of a range of cancers in humans and animals.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, announced today that John Martin, CEO, will present at Austrade's Mission on Regenerative Medicine Opportunities in Japan, on Monday 7 December in Tokyo and Wednesday 9 December in Kobe.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, announced today the commencement of a trial of its cancer vaccine technology, Kvax, in combination with chemotherapy as a treatment for canine lymphoma.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, announced today the commencement of a trial of its cancer vaccine technology, Kvax, in combination with chemotherapy as a treatment for canine lymphoma.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that it has secured exclusive rights to commercialise a breakthrough cell identification and selection technology that for the first time in the world allows high potency secreting stem cells to be identified and selected for the manufacture of next generation cell therapies.
